Equity Profile

MDGL

Madrigal Pharmaceuticals, Inc.

Health CareBiotechnology$12.2B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Madrigal Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for liver diseases and metabolic disorders....

Key Metrics to Watch

EPS

Earnings per share (EPS) will indicate the company's profitability and operational efficiency.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

MDGL Q2-2026 Earnings Preview

Context

Company Snapshot

Madrigal Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for liver diseases and metabolic disorders. With a market cap of $12 billion, it plays a significant role in the health care sector, particularly in addressing unmet medical needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-932.88%

Avg Stock Reaction

+4.22%

Last Quarter Recap

In Q1-2026, Madrigal reported an EPS of -$3.25, which was better than the expected -$3.61, resulting in a stock increase of 7.42% the following day. However, revenue details were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, especially given the company's recent ability to beat EPS estimates. However, the lack of revenue guidance raises concerns about future growth.

Bull Case

If Madrigal continues its trend of beating EPS estimates, it could signal strong operational performance and potentially lead to a positive market reaction.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, especially given the volatility in recent quarters.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be for Q2-2026?

This number will be crucial in assessing the company's financial health and operational efficiency, especially given the recent trend of beating estimates.

Will there be any revenue guidance provided?

Revenue guidance is essential for understanding future growth prospects and market demand for Madrigal's products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Madrigal's potential for a strong EPS beat due to recent operational improvements that are not fully reflected in current estimates.

Supporting Evidence

Madrigal has a 75% EPS beat rate in the last eight quarters, indicating a trend of exceeding expectations.

The stock has shown a strong positive reaction following earnings beats, suggesting that investor sentiment may be more favorable than anticipated.

Key Risk

If the EPS comes in better than -$3.00, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers around the company's ability to maintain or improve its earnings performance in light of recent volatility.

Bull Confirmed If

An EPS of less than -$3.00 would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS worse than -$3.50 would confirm the bear case, suggesting ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±25.88%

Historical Avg

±10.5%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect substantial volatility around the earnings report.

Options are pricing ±25.9% while MDGL has averaged ±10.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

37.7%

Calls (800)P/C Ratio: 0.57Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Madrigal beats expectations, history suggests a potential stock increase of around 6.18%, confirming positive operational trends.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors reassess future growth.

Miss

Should the company miss expectations, history indicates a likely decline of about 1.64%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on ongoing clinical trials and their timelines.
2Insights into market demand for Madrigal's products.
3Management's commentary on competitive landscape and positioning.
4Details on cost management strategies and operational efficiency.
5Any potential partnerships or collaborations that could impact growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Madrigal Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for liver diseases and metabolic disorders....

Key Metrics to Watch

EPS

Earnings per share (EPS) will indicate the company's profitability and operational efficiency.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

MDGL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-932.88%

Avg Stock Reaction

+4.22%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Madrigal continues its trend of beating EPS estimates, it could signal strong operational performance and potentially lead to a positive market reaction.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, especially given the volatility in recent quarters.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be for Q2-2026?

This number will be crucial in assessing the company's financial health and operational efficiency, especially given the recent trend of beating estimates.

Will there be any revenue guidance provided?

Revenue guidance is essential for understanding future growth prospects and market demand for Madrigal's products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Madrigal's potential for a strong EPS beat due to recent operational improvements that are not fully reflected in current estimates.

Supporting Evidence

Madrigal has a 75% EPS beat rate in the last eight quarters, indicating a trend of exceeding expectations.

The stock has shown a strong positive reaction following earnings beats, suggesting that investor sentiment may be more favorable than anticipated.

Key Risk

If the EPS comes in better than -$3.00, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers around the company's ability to maintain or improve its earnings performance in light of recent volatility.

Bull Confirmed If

An EPS of less than -$3.00 would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS worse than -$3.50 would confirm the bear case, suggesting ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±25.88%

Historical Avg

±10.5%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect substantial volatility around the earnings report.

Options are pricing ±25.9% while MDGL has averaged ±10.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

37.7%

Calls (800)P/C Ratio: 0.57Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Madrigal beats expectations, history suggests a potential stock increase of around 6.18%, confirming positive operational trends.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors reassess future growth.

Miss

Should the company miss expectations, history indicates a likely decline of about 1.64%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on ongoing clinical trials and their timelines.
2Insights into market demand for Madrigal's products.
3Management's commentary on competitive landscape and positioning.
4Details on cost management strategies and operational efficiency.
5Any potential partnerships or collaborations that could impact growth.